Convalescent Plasma Therapy in Immunocompromised Patients Infected With the BA.1 or BA.2 Omicron SARS‐CoV‐2-Reference-Cited by-同舟云学术

Convalescent Plasma Therapy in Immunocompromised Patients Infected With the BA.1 or BA.2 Omicron SARS‐CoV‐2

Published:2024-03 Issue:3 Volume:18 Page:
ISSN:1750-2640
Container-title:Influenza and Other Respiratory Viruses
language:en
Short-container-title:Influenza Resp Viruses

Author:

Richier Quentin¹^ORCID,De Valence Benjamin¹,Chopin Dorothée¹,Gras Emmanuelle¹²,Levi Laura I.¹²,Abi Aad Yasmine¹,Pacanowski Jérôme¹,Meynard Jean‐Luc¹,Plaçais Léo³,Fey Dorothée¹,Couture Priscille⁴,Martin‐Blondel Guillaume⁵⁶⁷,Pestre Vincent⁸,Woessner Juliette⁸,Ancellin Sophie⁹,Weyrich Pierre¹⁰,Carpentier Benjamin¹⁰,Idri Salim¹¹,Tiberghien Pierre¹²¹³,Surgers Laure¹²,Hueso Thomas¹⁴,Lacombe Karine¹²

Affiliation:

1. Service de Maladies Infectieuses Hôpital Saint‐Antoine, AP‐HP Paris France

2. Sorbonne Université, IPLESP, Inserm UMR‐S1136 Paris France

3. Département de Médecine Interne et Immunologie clinique Hôpital Bicêtre Le Kremlin‐Bicêtre France

4. Service de Médecine Interne Hôpital Foch Suresnes France

5. Service des Maladies Infectieuses et Tropicales Centre Hospitalier Universitaire de Toulouse Toulouse France

6. INSERM UMR1043, Centre de Physiopathologie de Toulouse‐Purpan Toulouse France

7. Faculté de Médecine Université de Toulouse Paul Sabatier Toulouse France

8. Service de médecine interne et maladies infectieuses Centre hospitalier Avignon Avignon France

9. Centre hospitalier d'Auch France

10. Unité d'Infectiologie, Groupement des Hôpitaux Catholiques de Lille, F‐59160 Lille France

11. Etablissement Français du Sang Créteil France

12. Etablissement Français du Sang La Plaine Saint‐Denis France

13. UMR 1098 RIGHT Inserm Université de Franche‐Comté, Etablissement Français du Sang Besançon France

14. Service d'hématologie clinique, Hôpital Avicenne, APHP, Sorbonne Université Paris‐Nord Bobigny France

Abstract

ABSTRACTThe emergence of SARS‐CoV‐2 Omicron variant has led to a complete reconfiguration of the therapeutic landscape, with all monoclonal antibodies having lost any neutralization activity. We report here a case series of 75 immunocompromised patients infected by the Omicron variant who benefited from COVID‐19 convalescent plasma (CCP). At Day 28, the overall survival was 76% (95% CI 67–86) with no significant difference in the clinical outcome between patients with hematological malignancies, solid organ transplantation or autoimmune diseases. No safety concern was reported during the course of the study. These results showed that CCP is well tolerated and represents a treatment option for immunocompromised patients who remain highly impacted by the COVID19 epidemic.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/irv.13272

Reference16 articles.

1. Insights From Early Clinical Trials Assessing Response to mRNA SARS-CoV-2 Vaccination in Immunocompromised Patients

2. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

3. Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19

4. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization

5. Early Outpatient Treatment for Covid-19 with Convalescent Plasma